TickerFactsScreenerDevelopers

Spero Therapeutics, Inc. (SPRO) — Operating Cash Flow

Annual figures by fiscal year, from SEC filings.

2016: -$28.96M2017: -$39.11M2018: -$39.62M2019: -$50.02M2020: -$85.87M2021: -$64.35M2022: -$7.73M2023: -$32.99M2024: -$23.44M2025: -$12.62M-$12.62M
2016Operating Cash Flow (USD)2025
Fiscal YearOperating Cash FlowChange YoY
2025-$12.62M+46.2%
2024-$23.44M+28.9%
2023-$32.99M-326.8%
2022-$7.73M+88.0%
2021-$64.35M+25.1%
2020-$85.87M-71.7%
2019-$50.02M-26.2%
2018-$39.62M-1.3%
2017-$39.11M-35.1%
2016-$28.96M—